Esra TERZİ DEMİRSOY, Ceren ERDOĞAN EROĞLU

Metotreksat İlişkili Pansitopeni ve Mukokütanöz Toksisite

Metotreksat onkolojik, romatolojik ve dermatolojik hastalıklar gibi çeşitli hastalıkların tedavisinde uzun yıllardır yaygın olarak kullanılmaktadır. Metotreksatın düşük doz kullanımı; nadiren kemik iliği supresyonu, mukokutanöz toksisite, hepatotoksisite, pulmoner fibrozis, böbrek yetmezliği gibi ciddi yan etkilere neden olabilir. Yaş, eşlik eden hastalıklar, proton pompa inhibitörü ve non-steroid anti-enflamatuar ilaçlar, metotreksatın haftalık yerine günlük kullanımı gibi çeşitli faktörler metotreksat toksisitesinin ortaya çıkmasını kolaylaştırmaktadır. Bu olgu sunumlarında kliniğimize pansitopeni ile başvuran olgulardan hareketle metotreksat toksisitesine yaklaşım ele alınacaktır.

Methotrexate-Induced Pancytopenia and Mucocutaneous Toxicity

Methotrexate has been widely used for many years in the treatment of variety of diseases including neoplastic, rheumatic and dermatological diseases. However, the use of low dose methotrexate rarely may cause side effect, such as bone marrow suppressions, mucocutaneous toxicity, hepatotoxicity, pulmonary fibrosis, renal dysfunction. Various factors facilitate the emergence of methotrexate toxicity; such as age, concomitant diseases, use of proton pump inhibitors and non-steroidal anti-inflammatory drugs, daily use of methotrexate instead of weekly. In these case reports; the approach to methotrexate toxicity will be discussed with reference to our patients with pancytopenia.

PDF

___

1. Demir FT, Tezcan Y, Türkoğlu Z, Başaran Ş: A case of Severe Low-dose Methotrexate-induced Toxicity. Med Bull Haseki. 2016; 54:252-254.
2. Arslan E, Özçelik F, Çakar M, Öztosun M, Demirbaş Ş, Sağlam K: Düşük Doz Oral Metotreksat Kullanımı ile Ortaya Çıkan Pansitopeni ve Deliryum Tablosu: Olgu Sunumu. Gülhane Tıp Derg. 2014;56: 182-184.
3. Brown PM, Pratt AG, Isaacs JD: Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016 Dec;12(12):731-742.
4. Goodman SM, Cronstein BN, Bykerk VP: Outcomes Related to Methotrexate Dose and Route of Administration in Patients with Rheumatoid Arthritis: A Systematic Literature Review. Clin Exp Rheumatol. 2015; 33(2): 272–278.
5. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R: Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther. 2014 Mar 1;36(3):427-35.
6. Cronsteın BN: Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis. Pharmacologıcal Revıews. 2005; 57:163-172.
7. Yélamos O, Català A, Vilarrasa E, Roé E, Puig L: Acute Severe Methotrexate Toxicity in Patients with Psoriasis: A Case Series and Discussion. Dermatology. 2014; 229:306-309.
8. Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H: Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014 Nov;13(11):1109-13.
9. Yıldız B, Erdoğan H, Bulur I, Aslan A, Saraçoğlu Z: Kutanöz ülserler ile seyreden akut metotreksat toksisitesi. Osmangazi Journal of Medicine. 2016;38:74-77.
10. Romão VC, Lima A, Bernardes M, Canhão H, Fonseca JE: Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? Immunol Res. 2014 Dec;60(2-3):289-310.
11. Demirkiran D, Kurt H, Yüksel M, Sari Y. Pancytopenia and Mucositis Encountered in the Early Stages of Methotrexate Treatment. Eur J Health Sci. 2017;3(1): XX.